2024 Q4 Form 10-Q Financial Statement
#000155837024015438 Filed on November 13, 2024
Income Statement
Concept | 2024 Q4 | 2024 Q3 |
---|---|---|
Revenue | ||
YoY Change | ||
Cost Of Revenue | ||
YoY Change | ||
Gross Profit | ||
YoY Change | ||
Gross Profit Margin | ||
Selling, General & Admin | ||
YoY Change | ||
% of Gross Profit | ||
Research & Development | ||
YoY Change | ||
% of Gross Profit | ||
Depreciation & Amortization | ||
YoY Change | ||
% of Gross Profit | ||
Operating Expenses | $519.0K | |
YoY Change | -97.03% | |
Operating Profit | -$519.0K | |
YoY Change | -97.03% | |
Interest Expense | ||
YoY Change | ||
% of Operating Profit | ||
Other Income/Expense, Net | -$55.00K | |
YoY Change | -77.08% | |
Pretax Income | $338.0K | |
YoY Change | -102.05% | |
Income Tax | ||
% Of Pretax Income | ||
Net Earnings | $300.0K | |
YoY Change | -101.82% | |
Net Earnings / Revenue | ||
Basic Earnings Per Share | -$0.02 | |
Diluted Earnings Per Share | -$0.02 | |
COMMON SHARES | ||
Basic Shares Outstanding | 16.10M | 16.10M |
Diluted Shares Outstanding | 16.10M |
Balance Sheet
Concept | 2024 Q4 | 2024 Q3 |
---|---|---|
SHORT-TERM ASSETS | ||
Cash & Short-Term Investments | ||
YoY Change | ||
Cash & Equivalents | $26.10M | |
Short-Term Investments | ||
Other Short-Term Assets | $930.0K | |
YoY Change | 20.16% | |
Inventory | ||
Prepaid Expenses | ||
Receivables | ||
Other Receivables | ||
Total Short-Term Assets | $58.25M | |
YoY Change | -42.19% | |
LONG-TERM ASSETS | ||
Property, Plant & Equipment | ||
YoY Change | ||
Goodwill | ||
YoY Change | ||
Intangibles | ||
YoY Change | ||
Long-Term Investments | ||
YoY Change | ||
Other Assets | ||
YoY Change | ||
Total Long-Term Assets | $0.00 | |
YoY Change | -100.0% | |
TOTAL ASSETS | ||
Total Short-Term Assets | $58.25M | |
Total Long-Term Assets | $0.00 | |
Total Assets | $58.25M | |
YoY Change | -46.05% | |
SHORT-TERM LIABILITIES | ||
YoY Change | ||
Accounts Payable | $437.0K | |
YoY Change | -69.44% | |
Accrued Expenses | ||
YoY Change | ||
Deferred Revenue | ||
YoY Change | ||
Short-Term Debt | ||
YoY Change | ||
Long-Term Debt Due | ||
YoY Change | ||
Total Short-Term Liabilities | $1.777M | |
YoY Change | -92.13% | |
LONG-TERM LIABILITIES | ||
Long-Term Debt | ||
YoY Change | ||
Other Long-Term Liabilities | ||
YoY Change | ||
Total Long-Term Liabilities | ||
YoY Change | ||
TOTAL LIABILITIES | ||
Total Short-Term Liabilities | $1.777M | |
Total Long-Term Liabilities | ||
Total Liabilities | $15.25M | |
YoY Change | -75.47% | |
SHAREHOLDERS EQUITY | ||
Retained Earnings | -$1.200B | |
YoY Change | 0.0% | |
Common Stock | $24.00K | |
YoY Change | 0.0% | |
Preferred Stock | ||
YoY Change | ||
Treasury Stock (at cost) | ||
YoY Change | ||
Treasury Stock Shares | ||
Shareholders Equity | $8.244M | |
YoY Change | ||
Total Liabilities & Shareholders Equity | $58.25M | |
YoY Change | -46.05% |
Cashflow Statement
Concept | 2024 Q4 | 2024 Q3 |
---|---|---|
OPERATING ACTIVITIES | ||
Net Income | $300.0K | |
YoY Change | -101.82% | |
Depreciation, Depletion And Amortization | ||
YoY Change | ||
Cash From Operating Activities | ||
YoY Change | ||
INVESTING ACTIVITIES | ||
Capital Expenditures | ||
YoY Change | ||
Acquisitions | ||
YoY Change | ||
Other Investing Activities | ||
YoY Change | ||
Cash From Investing Activities | ||
YoY Change | ||
FINANCING ACTIVITIES | ||
Cash Dividend Paid | ||
YoY Change | ||
Common Stock Issuance & Retirement, Net | ||
YoY Change | ||
Debt Paid & Issued, Net | ||
YoY Change | ||
Cash From Financing Activities | ||
YoY Change | ||
NET CHANGE | ||
Cash From Operating Activities | ||
Cash From Investing Activities | ||
Cash From Financing Activities | ||
Net Change In Cash | ||
YoY Change | ||
FREE CASH FLOW | ||
Cash From Operating Activities | ||
Capital Expenditures | ||
Free Cash Flow | ||
YoY Change |
Facts In Submission
Frame | Concept Type | Concept / XBRL Key | Value | Unit |
---|---|---|---|---|
CY2024Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
CY2023Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001759546 | ||
dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2024 | ||
dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
dei |
Amendment Flag
AmendmentFlag
|
false | ||
dei |
Security Exchange Name
SecurityExchangeName
|
NONE | ||
CY2023Q2 | us-gaap |
Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
|
0.067 | |
CY2023Q2 | us-gaap |
Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
|
0.067 | |
CY2024Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q2 | us-gaap |
Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
|
0.067 | |
us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
0 | ||
dei |
Document Type
DocumentType
|
10-Q | ||
dei |
Document Quarterly Report
DocumentQuarterlyReport
|
true | ||
dei |
Document Period End Date
DocumentPeriodEndDate
|
2024-09-30 | ||
dei |
Document Transition Report
DocumentTransitionReport
|
false | ||
dei |
Entity File Number
EntityFileNumber
|
001-38821 | ||
dei |
Entity Registrant Name
EntityRegistrantName
|
NU RIDE INC. | ||
dei |
Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
|
DE | ||
dei |
Entity Tax Identification Number
EntityTaxIdentificationNumber
|
83-2533239 | ||
dei |
Entity Address Address Line1
EntityAddressAddressLine1
|
1700 Broadway, 19th Floor | ||
dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
New York | ||
dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
NY | ||
dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
10019 | ||
dei |
City Area Code
CityAreaCode
|
212 | ||
dei |
Local Phone Number
LocalPhoneNumber
|
202-2200 | ||
dei |
Security12b Title
Security12bTitle
|
Class A common stock | ||
dei |
Trading Symbol
TradingSymbol
|
NRDE | ||
dei |
Entity Current Reporting Status
EntityCurrentReportingStatus
|
Yes | ||
dei |
Entity Interactive Data Current
EntityInteractiveDataCurrent
|
Yes | ||
dei |
Entity Filer Category
EntityFilerCategory
|
Non-accelerated Filer | ||
dei |
Entity Small Business
EntitySmallBusiness
|
true | ||
dei |
Entity Emerging Growth Company
EntityEmergingGrowthCompany
|
false | ||
dei |
Entity Shell Company
EntityShellCompany
|
true | ||
CY2024Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
16096296 | |
CY2024Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
26096000 | |
CY2023Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
87096000 | |
CY2024Q3 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
30925000 | |
CY2024Q3 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
300000 | |
CY2023Q4 | us-gaap |
Prepaid Insurance
PrepaidInsurance
|
2825000 | |
CY2024Q3 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
930000 | |
CY2023Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
2218000 | |
CY2024Q3 | us-gaap |
Assets Current
AssetsCurrent
|
58251000 | |
CY2023Q4 | us-gaap |
Assets Current
AssetsCurrent
|
92139000 | |
CY2023Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
30000 | |
CY2024Q3 | us-gaap |
Assets
Assets
|
58251000 | |
CY2023Q4 | us-gaap |
Assets
Assets
|
92169000 | |
CY2024Q3 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
437000 | |
CY2023Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
933000 | |
CY2024Q3 | us-gaap |
Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
|
934000 | |
CY2023Q4 | us-gaap |
Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
|
12815000 | |
CY2024Q3 | nrde |
Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
|
406000 | |
CY2023Q4 | nrde |
Accrued And Other Liabilities Current
AccruedAndOtherLiabilitiesCurrent
|
1650000 | |
CY2024Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
1777000 | |
CY2023Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
15398000 | |
CY2024Q3 | us-gaap |
Liabilities Subject To Compromise
LiabilitiesSubjectToCompromise
|
13470000 | |
CY2023Q4 | us-gaap |
Liabilities Subject To Compromise
LiabilitiesSubjectToCompromise
|
30467000 | |
CY2024Q3 | us-gaap |
Liabilities
Liabilities
|
15247000 | |
CY2023Q4 | us-gaap |
Liabilities
Liabilities
|
45865000 | |
CY2024Q3 | us-gaap |
Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
|
0.0001 | |
CY2023Q4 | us-gaap |
Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
|
0.0001 | |
CY2024Q3 | us-gaap |
Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
|
12000000 | |
CY2023Q4 | us-gaap |
Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
|
12000000 | |
CY2024Q3 | us-gaap |
Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
|
300000 | |
CY2023Q4 | us-gaap |
Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
|
300000 | |
CY2024Q3 | us-gaap |
Temporary Equity Shares Issued
TemporaryEquitySharesIssued
|
300000 | |
CY2023Q4 | us-gaap |
Temporary Equity Shares Issued
TemporaryEquitySharesIssued
|
300000 | |
CY2024Q3 | us-gaap |
Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
|
34760000 | |
CY2023Q4 | us-gaap |
Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
|
32755000 | |
CY2024Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2023Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.0001 | |
CY2024Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
450000000 | |
CY2023Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
450000000 | |
CY2024Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
16100692 | |
CY2024Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
16100692 | |
CY2023Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
15953212 | |
CY2023Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
15953212 | |
CY2024Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
24000 | |
CY2023Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
24000 | |
CY2024Q3 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
1185156000 | |
CY2023Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
1183804000 | |
CY2024Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1176936000 | |
CY2023Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1170279000 | |
CY2024Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
8244000 | |
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
13549000 | |
CY2024Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
58251000 | |
CY2023Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
92169000 | |
us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
2340000 | ||
us-gaap |
Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
|
91550000 | ||
CY2024Q3 | nrde |
Selling General And Administrative Income Expense
SellingGeneralAndAdministrativeIncomeExpense
|
2308000 | |
CY2023Q3 | nrde |
Selling General And Administrative Income Expense
SellingGeneralAndAdministrativeIncomeExpense
|
-2600000 | |
nrde |
Selling General And Administrative Income Expense
SellingGeneralAndAdministrativeIncomeExpense
|
9033000 | ||
nrde |
Selling General And Administrative Income Expense
SellingGeneralAndAdministrativeIncomeExpense
|
69775000 | ||
CY2023Q3 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
5716000 | |
us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
32445000 | ||
CY2024Q3 | nrde |
Legal And Litigation Accruals
LegalAndLitigationAccruals
|
-1789000 | |
nrde |
Legal And Litigation Accruals
LegalAndLitigationAccruals
|
-4348000 | ||
CY2023Q3 | us-gaap |
Debtor Reorganization Items Other Expense Income
DebtorReorganizationItemsOtherExpenseIncome
|
13641000 | |
us-gaap |
Debtor Reorganization Items Other Expense Income
DebtorReorganizationItemsOtherExpenseIncome
|
4785000 | ||
us-gaap |
Debtor Reorganization Items Other Expense Income
DebtorReorganizationItemsOtherExpenseIncome
|
13641000 | ||
CY2023Q3 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
738000 | |
us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
140219000 | ||
CY2024Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
519000 | |
CY2023Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
17495000 | |
us-gaap |
Operating Expenses
OperatingExpenses
|
9470000 | ||
us-gaap |
Operating Expenses
OperatingExpenses
|
256080000 | ||
CY2024Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-519000 | |
CY2023Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-17495000 | |
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-9470000 | ||
us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-345290000 | ||
CY2023Q3 | us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-175000 | |
us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-2784000 | ||
CY2024Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-55000 | |
CY2023Q3 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-240000 | |
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-217000 | ||
us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-83000 | ||
CY2024Q3 | nrde |
Investment And Interest Income Expense Nonoperating Net
InvestmentAndInterestIncomeExpenseNonoperatingNet
|
912000 | |
CY2023Q3 | nrde |
Investment And Interest Income Expense Nonoperating Net
InvestmentAndInterestIncomeExpenseNonoperatingNet
|
1404000 | |
nrde |
Investment And Interest Income Expense Nonoperating Net
InvestmentAndInterestIncomeExpenseNonoperatingNet
|
3030000 | ||
nrde |
Investment And Interest Income Expense Nonoperating Net
InvestmentAndInterestIncomeExpenseNonoperatingNet
|
5440000 | ||
CY2024Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
338000 | |
CY2023Q3 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-16506000 | |
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-6657000 | ||
us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-342717000 | ||
CY2024Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
338000 | |
CY2023Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-16506000 | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-6657000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-342717000 | ||
CY2024Q3 | nrde |
Dividend Preferred Stock
DividendPreferredStock
|
682000 | |
CY2023Q3 | nrde |
Dividend Preferred Stock
DividendPreferredStock
|
-630000 | |
nrde |
Dividend Preferred Stock
DividendPreferredStock
|
2005000 | ||
nrde |
Dividend Preferred Stock
DividendPreferredStock
|
-1852000 | ||
CY2024Q3 | nrde |
Net Income Loss To Common Shareholders
NetIncomeLossToCommonShareholders
|
-344000 | |
CY2023Q3 | nrde |
Net Income Loss To Common Shareholders
NetIncomeLossToCommonShareholders
|
-15876000 | |
nrde |
Net Income Loss To Common Shareholders
NetIncomeLossToCommonShareholders
|
-8662000 | ||
nrde |
Net Income Loss To Common Shareholders
NetIncomeLossToCommonShareholders
|
-340865000 | ||
CY2024Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.02 | |
CY2024Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.02 | |
CY2023Q3 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-1.03 | |
CY2023Q3 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-1.03 | |
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.54 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.54 | ||
us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-21.38 | ||
us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-21.38 | ||
CY2024Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
16096000 | |
CY2024Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
16096000 | |
CY2023Q3 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
15953000 | |
CY2023Q3 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
15953000 | |
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
16058000 | ||
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
16058000 | ||
us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
15942000 | ||
us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
15942000 | ||
CY2024Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
8543000 | |
CY2024Q3 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
45000 | |
CY2024Q3 | nrde |
Adjustments To Additional Paid In Capital Temporary Equity Dividend Accretion
AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDividendAccretion
|
682000 | |
CY2024Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
338000 | |
CY2024Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
8244000 | |
CY2023Q2 | us-gaap |
Stockholders Equity
StockholdersEquity
|
28972000 | |
CY2023Q3 | us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
1855000 | |
CY2023Q3 | nrde |
Adjustments To Additional Paid In Capital Temporary Equity Dividend Accretion
AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDividendAccretion
|
630000 | |
CY2023Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-16506000 | |
CY2023Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
13691000 | |
CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
13549000 | |
us-gaap |
Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
|
-106000 | ||
us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
3463000 | ||
nrde |
Adjustments To Additional Paid In Capital Temporary Equity Dividend Accretion
AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDividendAccretion
|
2005000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-6657000 | ||
CY2024Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
8244000 | |
CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
351772000 | |
us-gaap |
Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
|
-65000 | ||
us-gaap |
Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
|
6553000 | ||
nrde |
Adjustments To Additional Paid In Capital Temporary Equity Dividend Accretion
AdjustmentsToAdditionalPaidInCapitalTemporaryEquityDividendAccretion
|
1852000 | ||
us-gaap |
Net Income Loss
NetIncomeLoss
|
-342717000 | ||
CY2023Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
13691000 | |
us-gaap |
Profit Loss
ProfitLoss
|
-6657000 | ||
us-gaap |
Profit Loss
ProfitLoss
|
-342717000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
3463000 | ||
us-gaap |
Share Based Compensation
ShareBasedCompensation
|
6553000 | ||
us-gaap |
Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
|
-2784000 | ||
us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
140219000 | ||
nrde |
Depreciation Depletion And Amortization Of Plant And Property
DepreciationDepletionAndAmortizationOfPlantAndProperty
|
54407000 | ||
us-gaap |
Inventory Write Down
InventoryWriteDown
|
24105000 | ||
nrde |
Other Non Cash Changes
OtherNonCashChanges
|
-2183000 | ||
us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
10537000 | ||
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-3843000 | ||
us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-13337000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-496000 | ||
us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-11353000 | ||
nrde |
Accrued Legal And Professional Expenses Credits
AccruedLegalAndProfessionalExpensesCredits
|
-11881000 | ||
nrde |
Accrued Legal And Professional Expenses Credits
AccruedLegalAndProfessionalExpensesCredits
|
-25061000 | ||
nrde |
Increase Decrease In Accrued Liabilities And Due To Related Party
IncreaseDecreaseInAccruedLiabilitiesAndDueToRelatedParty
|
-18241000 | ||
nrde |
Increase Decrease In Accrued Liabilities And Due To Related Party
IncreaseDecreaseInAccruedLiabilitiesAndDueToRelatedParty
|
30440000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-29969000 | ||
us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-120006000 | ||
us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
10152000 | ||
us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
32147000 | ||
us-gaap |
Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
|
134203000 | ||
us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
397000 | ||
us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
92301000 | ||
us-gaap |
Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
|
106000 | ||
us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-106000 | ||
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-30075000 | ||
us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-27705000 | ||
CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
87096000 | |
CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
121358000 | |
CY2024Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
57021000 | |
CY2023Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
93653000 | |
nrde |
Payment For Debtor Reorganization Items
PaymentForDebtorReorganizationItems
|
25781000 | ||
CY2024Q3 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
26100000 | |
CY2024Q3 | us-gaap |
Restricted Cash
RestrictedCash
|
30900000 | |
CY2024Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-1200000000 | |
CY2024Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
300000 | |
us-gaap |
Net Income Loss
NetIncomeLoss
|
-6700000 | ||
us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;padding-bottom:10pt;margin:0pt;"><i style="font-style:italic;font-weight:normal;">Use of Estimates in Financial Statement Preparation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;background:#ffffff;margin:0pt 0pt 10pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">The preparation of condensed consolidated financial statements in accordance with GAAP is based on the selection and application of accounting policies that require us to make significant estimates and assumptions that affect the reported amounts in the condensed consolidated financial statements, and related disclosures in the accompanying notes to the financial statements. Actual results could differ from those estimates. Estimates and assumptions are periodically reviewed and the effects of changes are reflected in the condensed consolidated financial statements in the period they are determined to be necessary. The Chapter 11 Cases may result in ongoing, additional changes in facts and circumstances that may cause the Company’s estimates and assumptions to change, potentially materially. The Company undertakes no obligation to update or revise any of the disclosures, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">There have been no material changes to the critical accounting policies and estimates described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023.</p> | ||
CY2024Q3 | nrde |
Percentage Of Emerging Entity S Voting Shares To Be Received By Existing Voting Shareholders Immediately Prior To Confirmation
PercentageOfEmergingEntitySVotingSharesToBeReceivedByExistingVotingShareholdersImmediatelyPriorToConfirmation
|
0.50 | |
us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | ||
us-gaap |
Number Of Reportable Segments
NumberOfReportableSegments
|
1 | ||
CY2024Q3 | nrde |
Reserve For Claims Of General Unsecured Creditors
ReserveForClaimsOfGeneralUnsecuredCreditors
|
45000000 | |
CY2024Q3 | us-gaap |
Escrow Deposit
EscrowDeposit
|
27300000 | |
CY2024Q3 | nrde |
Reserve For Claims Of General Unsecured Creditors
ReserveForClaimsOfGeneralUnsecuredCreditors
|
45000000 | |
CY2024Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
26096000 | |
CY2023Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
87096000 | |
CY2024Q3 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
30925000 | |
CY2024Q3 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
57021000 | |
CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
87096000 | |
us-gaap |
Inventory Write Down
InventoryWriteDown
|
0 | ||
CY2024Q3 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
0 | |
CY2023Q3 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
700000 | |
us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
140200000 | ||
us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
0 | ||
CY2024Q3 | us-gaap |
Asset Impairment Charges
AssetImpairmentCharges
|
0 | |
us-gaap |
Derivatives Embedded Derivatives
DerivativesEmbeddedDerivatives
|
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 10pt 0pt;"><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">Warrants</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">The Company accounted for its warrants in accordance with the guidance contained in Accounting Standards Codification 815: </span><i style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;">Derivatives and Hedging</i><span style="font-family:'Arial','Helvetica','sans-serif';"> (“ASC 815”) 815-40-15-7D and 7F under which the warrants did not meet the criteria for equity treatment and were recorded as liabilities at their fair value at each reporting period. Any change in fair value was recognized in the statement of operations. As a result of the Chapter 11 Cases, the fair value of the Company’s warrants was deemed to be </span><span style="font-family:'Arial','Helvetica','sans-serif';">zero</span><span style="font-family:'Arial','Helvetica','sans-serif';"> and adjusted accordingly as of June 30, 2023.The fair value of the Company’s warrants is currently deemed to be </span><span style="font-family:'Arial','Helvetica','sans-serif';">zero</span><span style="font-family:'Arial','Helvetica','sans-serif';">.</span></p> | ||
CY2023Q2 | us-gaap |
Derivative Liabilities
DerivativeLiabilities
|
0 | |
CY2024Q3 | us-gaap |
Derivative Liabilities
DerivativeLiabilities
|
0 | |
us-gaap |
Sales Commissions And Fees
SalesCommissionsAndFees
|
0 | ||
CY2023 | us-gaap |
Sales Commissions And Fees
SalesCommissionsAndFees
|
0 | |
us-gaap |
Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
|
0 | ||
CY2024Q3 | nrde |
Debtor Reorganization Items Number Of Vehicles Repurchased And Sold
DebtorReorganizationItemsNumberOfVehiclesRepurchasedAndSold
|
3 | |
CY2024Q3 | nrde |
Debtor Reorganization Items Number Of Vehicles Repurchased And Sold
DebtorReorganizationItemsNumberOfVehiclesRepurchasedAndSold
|
3 | |
us-gaap |
Debtor Reorganization Items Other Expense Income
DebtorReorganizationItemsOtherExpenseIncome
|
4800000 | ||
us-gaap |
Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
|
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Reclassifications</i></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt;">Certain reclassifications have been made in the presentation of the prior period balance sheet related to prepaid expenses, prepaid insurance, and other current assets as well as to the prior period statement of cash flows </p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">related to accrued legal and professional and accrued expenses and other liabilities to conform with the September 30, 2024 presentation.</p> | ||
CY2023Q2 | us-gaap |
Derivative Liabilities
DerivativeLiabilities
|
0 | |
CY2023Q3 | us-gaap |
Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
|
0 | |
CY2023Q3 | us-gaap |
Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
|
700000 | |
CY2023Q3 | us-gaap |
Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
|
0 | |
us-gaap |
Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
|
700000 | ||
CY2023Q3 | us-gaap |
Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
|
700000 | |
us-gaap |
Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
|
0 | ||
CY2024Q3 | us-gaap |
Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
|
0 | |
CY2024Q3 | us-gaap |
Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
|
0.0001 | |
CY2024Q3 | us-gaap |
Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
|
34800000 | |
CY2023Q4 | us-gaap |
Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
|
32800000 | |
us-gaap |
Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
|
30000000.0 | ||
CY2024Q3 | us-gaap |
Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
|
30000000.0 | |
CY2024Q3 | nrde |
Shares Authorized Common And Preferred
SharesAuthorizedCommonAndPreferred
|
462000000 | |
CY2024Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
450000000 | |
CY2024Q3 | us-gaap |
Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
|
12000000 | |
CY2024Q3 | us-gaap |
Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
|
0.0001 | |
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
1441000 | ||
us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
1468000 | ||
nrde |
Termination Period For Options Not Exercised Upon Officer S Or Director S Termination
TerminationPeriodForOptionsNotExercisedUponOfficerSOrDirectorSTermination
|
P3M | ||
nrde |
Shares Issued For Awards Vested During Pendency Of Chapter11 Cases
SharesIssuedForAwardsVestedDuringPendencyOfChapter11Cases
|
101947 | ||
us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Accelerated Vesting Number
SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
|
102889 | ||
CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
|
2600000 | |
CY2024Q1 | nrde |
Share Based Payment Arrangement Non Accelerated Cost
ShareBasedPaymentArrangementNonAcceleratedCost
|
800000 | |
CY2023Q3 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
60700000 | |
CY2024Q3 | us-gaap |
Bankruptcy Claims Amount Of Claims Settled
BankruptcyClaimsAmountOfClaimsSettled
|
29800000 | |
CY2024Q3 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
30900000 | |
CY2023Q3 | us-gaap |
Liabilities Subject To Compromise
LiabilitiesSubjectToCompromise
|
29900000 | |
us-gaap |
Liabilities Subject To Compromise Payments Under Bankruptcy Court Order For Resolutions Of Contingencies Subject To Chapter11
LiabilitiesSubjectToCompromisePaymentsUnderBankruptcyCourtOrderForResolutionsOfContingenciesSubjectToChapter11
|
16400000 | ||
CY2024Q3 | us-gaap |
Liabilities Subject To Compromise
LiabilitiesSubjectToCompromise
|
13500000 | |
nrde |
Loss Contingency Number Of Subpoenas Received
LossContingencyNumberOfSubpoenasReceived
|
2 | ||
us-gaap |
Bankruptcy Claims Amount Of Claims Filed
BankruptcyClaimsAmountOfClaimsFiled
|
45000000.0 | ||
nrde |
Number Of Vehicles Repurchased
NumberOfVehiclesRepurchased
|
35 | ||
nrde |
Number Of Still In Use Vehicles Repurchased
NumberOfStillInUseVehiclesRepurchased
|
3 | ||
CY2024Q3 | ecd |
Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
|
false | |
CY2024Q3 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
CY2024Q3 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false | |
CY2024Q3 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false |